Siglec-5/CD170[Biotin], His & Avi, Human
| $660.00 | |
| Z04599-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $660.00 | |
| Z04599-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 49.3 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, 350mM NaCl (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
The purity of Siglec-5/CD170[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
Siglec-5/CD170[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Siglecs (sialic acid binding Ig-like lectins) are I-type (Ig-type) lectins belonging to the Ig superfamily. They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding, followed by varying numbers of Ig-like C2-type domains. Siglec 5 is putative adhesion molecule that mediates sialic-acid dependent binding to cells. Binds equally to alpha-2,3-linked and alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. |
| Synonyms | CD170; CD33 antigen-like 2; CD33L2; OBBP2; Siglec5; SIGLEC5; OB-BP2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.